Pre-made Vadastuximab Talirine benchmark antibody (Whole mAb ADC, anti-CD33 therapeutic antibody, Anti-SIGLEC-3/SIGLEC3/p67 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Vadastuximab Talirine benchmark antibody (Whole mAb ADC, anti-CD33 therapeutic antibody, Anti-SIGLEC-3/SIGLEC3/p67 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vadastuximab talirine or SGN-CD33A is an antibody-drug conjugate or ADC directed to CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. The trial drug, being developed by Seattle Genetics and was in clinical trials for the treatment of acute myeloid leukemia (AML).[1][2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1042-1mg	1mg	Inquiry
GMP-Bios-INN-1042-10mg	10mg	Inquiry
GMP-Bios-INN-1042-100mg	100mg	Inquiry
GMP-Bios-INN-1042-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Vadastuximab Talirine Biosimilar, Whole Mab Adc, Anti-Cd33 Antibody: Anti-SIGLEC-3/SIGLEC3/p67 therapeutic antibody Drug Conjugate
INN Name	Vadastuximab Talirine
Target	CD33
Format	Whole mAb ADC
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Seattle genetics, Inc. (Bothell WA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0